TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05131698

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tislelizumab and Lenvatinib
Description: TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight \< 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)
Study: NCT05415839

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser
Study: NCT05907629

Intervention type: OTHER
Intervention: MRI
Description: Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
Study: NCT04709770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-liters polyethylene glycol with citrate and simethicone
Description: Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-liters polyethylene glycol with simethicone
Description: High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-residue diet
Description: Diet before colonoscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Diet before colonoscopy.
Study: NCT06295250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manualized Group Based Psychotherapy
Description: Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized Group Based Psychotherapy
Description: Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poverty Alleviation
Description: This intervention includes Asset transfer, skill transfer, financial literacy education, stipend, savings accounts, veterinary support, feed, and agricultural training
Study: NCT06218693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIA Family
Description: A family-based, multi-component, individual-tailored intervention based on case-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: care as usual
Study: NCT05006911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound
Description: To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
Study: NCT05742594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered orally.
Study: NCT05395715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
Study: NCT05416502

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
Study: NCT03660540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
Study: NCT04819568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT04832893

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: steady intensity aerobic test of 30 minutes long
Description: the use of different type of masks during an aerobic exercise

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: steady intensity aerobic test of 30 minutes long
Description: the use of different type of masks during an aerobic exercise

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: steady intensity aerobic test of 30 minutes long
Description: the use of different type of masks during an aerobic exercise
Study: NCT04360096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYESAMI™ (aviptadil acetate)
Description: Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline Inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulized administration of ZYESAMI™ or Placebo
Description: Use of 510(k) cleared mesh nebulizer to deliver investigational product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulized administration of ZYESAMI™ or Placebo
Description: Use of 510(k) cleared mesh nebulizer to deliver investigational product
Study: NCT05144490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A single session of bodyweight exercise
Study: NCT05151666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray
Description: The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
Study: NCT05030597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-FAPI
Description: Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
Study: NCT04836091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist
Description: From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
Study: NCT04978480

Intervention type: OTHER
Intervention: no intervention
Description: There is no intervention. We are only collecting standard of care data.
Study: NCT05868200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capitano zenzero toothpaste
Description: Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
Study: NCT06228443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Film-coated Tablet
Description: Leflunomide 20 mg Film-coated Tablet (Test Drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA® 20 mg Film-coated Tablet
Description: ARAVA® 20 mg Tablets (Reference Drug)
Study: NCT05868200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate total toothpaste
Description: Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
Study: NCT05574699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Risk Score and CDS Tool
Description: A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
Study: NCT05256953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block + general anesthesia
Description: Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only general anesthesia
Description: Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day).
Study: NCT06032988

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LactoLevure
Description: Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LactoLevure
Description: Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.
Study: NCT06439043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR Psychotherapy
Description: EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
Study: NCT06007066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 capsule
Description: Subjects will be given 40mg or 60mg of HSK16149 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 capsule
Description: Subjects will be given 40mg or 60mg of HSK16149 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 capsule
Description: Subjects will be given 40mg or 60mg of HSK16149 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 capsule
Description: Subjects will be given 40mg or 60mg of HSK16149 orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given HSK16149 placebo orally.
Study: NCT05234593

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EmpowerPlus Lightning Sticks
Description: multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
Study: NCT05068453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
Description: OH2：less than 8mL/time，Q2W，i.t.；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody for injection
Description: HX-008：200mg/time，Q3W，i.v.；

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: 3 times radiation，totally 24-30 Gy for each lession.
Study: NCT06344936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
Description: Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
Study: NCT06439043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online EMDR Psychotherapy
Description: Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
Study: NCT06648928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Supported PTSD Coach
Description: Combines self-managed PTSD Coach application with four 20-30 minute sessions delivered by a clinician. The app includes modules on learning about PTSD, self-assessment, symptom management, and finding support.
Study: NCT05078307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OHR VS OHV
Description: Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OHR VS OHV
Description: Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid.
Study: NCT05345938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
Study: NCT04878289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOTAL with Motivational Telemedicine Sessions
Description: Teaching Obesity Treatment Options to Adult Learners Educational Video with 3, 30 minute motivational sessions at 1 week, 6 months, and 12 months after viewing video
Study: NCT06156449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme oil
Description: The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature\&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
Study: NCT05975372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blossom tissue expander
Description: Mentor spectrum adjustable saline breast implant for expansion is placed with the Blossom tissue expander above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard tissue expansion
Description: Mentor spectrum adjustable saline breast implant for expansion is placed with (without the Blossom tissue expander) above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
Study: NCT04498468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained Release Dexamethasone, 0.4 mg
Description: dexamethasone 0.4mg lacrimal insert

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
Description: Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
Study: NCT05339204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allo-HSCT
Description: allo-HSCT from any type of donor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo-HSCT
Description: allo-HSCT from any type of donor
Study: NCT05280236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol TIVA
Description: Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam TIVA
Description: Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
Study: NCT05522855

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG Sensorband and mobile application
Description: EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Sensorband and mobile application
Description: EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
Study: NCT05009238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar stabilization exercises
Description: selected exercises will taught to participant and practiced 3 times per week for 6 weeks
Study: NCT06450808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Microalgae biomass
Description: The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Microalgae biomass
Description: The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Microalgae biomass
Description: The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.